Paul Tudor Jones’s Pacific Biosciences PACB Stock Holding History

Paul Tudor Jones’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.15M	Hold	684,707	–	–	﹤0.01%	2317
2026 Q1	$904K	Buy	+684,707	New	+$1.22M	﹤0.01%	2442
2024 Q4	–	Sell	-78,171	Closed	-$133K	–	3385
2024 Q3	$133K	Buy	+78,171	New	+$128K	﹤0.01%	2570
2024 Q2	–	Sell	-291,569	Closed	-$1.09M	–	2666
2024 Q1	$1.09M	Buy	+291,569	New	+$1.71M	0.01%	1292
2023 Q1	–	Sell	-139,197	Closed	-$1.14M	–	2817
2022 Q4	$1.14M	Buy	+139,197	New	+$1.2M	0.02%	1016
2022 Q3	–	Sell	-493,119	Closed	-$2.18M	–	2598
2022 Q2	$2.18M	Buy	+493,119	New	+$3M	0.06%	470
2018 Q1	–	Sell	-58,203	Closed	-$154K	–	1174
2017 Q4	$154K	Buy	+58,203	New	+$204K	﹤0.01%	999
2017 Q1	–	Sell	-78,879	Closed	-$300K	–	1508
2016 Q4	$300K	Buy	+78,879	New	+$573K	0.01%	1024
2016 Q3	–	Sell	-32,921	Closed	-$232K	–	1643
2016 Q2	$232K	Buy	32,921 +14,121	+75%	+$129K	﹤0.01%	1326
2016 Q1	$160K	Buy	+18,800	New	+$185K	﹤0.01%	1548
2015 Q3	–	Sell	-30,400	Closed	-$175K	–	1693
2015 Q2	$175K	Buy	30,400 +4,700	+18%	+$27.2K	0.01%	1361
2015 Q1	$150K	Buy	+25,700	New	+$177K	﹤0.01%	1338

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Paul Tudor Jones's PACB Position: Q2 2026 in Review

Paul Tudor Jones held its Pacific Biosciences (PACB) position steady in Q2 2026 at 684,707 shares worth $1.15M. The position accounts for ﹤0.01% of the portfolio, ranked #2317.

Paul Tudor Jones first reported a position in PACB in Q1 2015 and has held it in 12 quarters since. The position peaked at $2.18M in Q2 2022. 222 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

Paul Tudor Jones held 684,707 shares of Pacific Biosciences worth $1.15M as of Q2 2026.
Paul Tudor Jones left its Pacific Biosciences share count unchanged in Q2 2026.
Pacific Biosciences made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #2317 holding.
Paul Tudor Jones first reported a position in Pacific Biosciences in Q1 2015 and has held it in 12 quarters since.
Paul Tudor Jones's Pacific Biosciences position peaked at $2.18M in Q2 2022.
222 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.